Image 1
Bupropion Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 0591-3543
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Bupropion Hydrochloride (NDC 0591-3543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
This is a medication called BuPROPion HCI Extended-Release Tablets, USP (SR) for which 60 tablets are dispensed with a medication guide. It contains 150mg of Bupropion Hydrochloride and should not be used in combination with other medications containing upropion hydrochloride. The medication is manufactured by Actavis Laboratories FL Inc and distributed by Actavis Pharma. Dosage information can be found in the package insert and it should be stored at controlled room temperature away from children. The trademarks Wellbutrine, Wellbutrin SR, and Wellbutrin XL are referenced.*
Image 3
This text appears to be advertising a prescription medicine for smoking cessation called Bupropion HCl Extended-Release Tablets, USP (SR). The tablets come in a bottle of 60 and are meant to be taken twice a day after the initial titration. The medicine is only available through a healthcare professional and comes with a medication guide and a plan to succeed workbook. The text also mentions that the product should not be used with medicines containing bupropion HCl.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
